AU5939901A - Methods of treating vascular diseases characterized by nitric oxide insufficiency - Google Patents

Methods of treating vascular diseases characterized by nitric oxide insufficiency

Info

Publication number
AU5939901A
AU5939901A AU5939901A AU5939901A AU5939901A AU 5939901 A AU5939901 A AU 5939901A AU 5939901 A AU5939901 A AU 5939901A AU 5939901 A AU5939901 A AU 5939901A AU 5939901 A AU5939901 A AU 5939901A
Authority
AU
Australia
Prior art keywords
methods
nitric oxide
vascular diseases
diseases characterized
treating vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU5939901A
Other languages
English (en)
Inventor
Joseph Loscalzo
Joseph A Vita
Michael D Loberg
Manuel Worcel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Nitromed Inc
Original Assignee
Boston University
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/029528 external-priority patent/WO2001035961A1/en
Application filed by Boston University, Nitromed Inc filed Critical Boston University
Publication of AU5939901A publication Critical patent/AU5939901A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU5939901A 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency Pending AU5939901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2000/029528 WO2001035961A1 (en) 1999-10-29 2000-10-27 Methods of treating vascular diseases characterized by nitric oxide insufficiency
US09/697,317 US6635273B1 (en) 1999-10-29 2000-10-27 Methods of treating vascular diseases characterized by nitric oxide insufficiency
PCT/US2001/014245 WO2002034303A1 (en) 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency

Publications (1)

Publication Number Publication Date
AU5939901A true AU5939901A (en) 2002-05-06

Family

ID=27663595

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001259399A Ceased AU2001259399B2 (en) 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU5939901A Pending AU5939901A (en) 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2006236103A Ceased AU2006236103B2 (en) 2000-10-27 2006-11-16 Methods of treating vascular diseases characterized by nitric oxide insufficiency

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001259399A Ceased AU2001259399B2 (en) 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2006236103A Ceased AU2006236103B2 (en) 2000-10-27 2006-11-16 Methods of treating vascular diseases characterized by nitric oxide insufficiency

Country Status (5)

Country Link
EP (1) EP1337283A4 (ja)
JP (1) JP2004521083A (ja)
AU (3) AU2001259399B2 (ja)
CA (2) CA2678256A1 (ja)
WO (1) WO2002034303A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104366475A (zh) * 2014-11-10 2015-02-25 罗会明 一种增强型保健品

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212053A4 (en) 1999-09-08 2004-08-11 Nitromed Inc METHODS FOR THE TREATMENT AND PROPHYLAXIS OF CONGESTIVE HEART FAILURE BY HYDRALAZIN COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE
FR2832634A1 (fr) * 2001-11-29 2003-05-30 Univ Pasteur Utilisation des isomeres l de derives aminoacides de l'hydroxyguanidine pour la production de no, compositions pharmaceutiques les contenant et utilisations pharmaceutiques
AU2003286389A1 (en) * 2002-11-29 2004-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
CA2536827C (en) 2003-07-09 2014-09-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
WO2005107384A2 (en) * 2004-03-31 2005-11-17 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
JP4949661B2 (ja) * 2004-09-21 2012-06-13 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物
TW200612896A (en) * 2004-09-21 2006-05-01 Sankyo Co Pharmaceutical compositions containing with HMG-CoA reductase inhibitor and glutathione
JP2008535858A (ja) * 2005-04-07 2008-09-04 ニトロメッド インコーポレーティッド 心不全における遺伝リスク、すなわちｎｏｓ３の遺伝子変異の影響の評価方法
US20070098791A1 (en) * 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
US20070098796A1 (en) 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
US20070232671A1 (en) * 2006-03-13 2007-10-04 Given Bruce D Methods and compositions for treatment of diastolic heart failure
WO2007136626A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
EP2123266B1 (en) 2006-12-06 2014-01-15 Kaneka Corporation Cancer therapeutic agent and anti-carcinogenic agent
US20150011463A1 (en) * 2012-02-15 2015-01-08 Kyowa Hakko Bio Co., Ltd. Agent for preventing or ameliorating vascular endothelial malfunction
EP2914257B1 (en) * 2012-10-30 2019-04-03 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
US20160008394A1 (en) 2013-02-28 2016-01-14 Aires Pharmaceuticals, Inc. Inorganic nitrite to improve cardiopulmonary hemodynamics
WO2023244805A1 (en) * 2022-06-16 2023-12-21 Georgia Tech Research Corporation Anti-vwf therapeutic for preventing arterial thrombi

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584315A (en) * 1981-11-16 1986-04-22 The Upjohn Company Method of treating ischemic states
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
ATE110954T1 (de) * 1988-01-29 1994-09-15 Peter H Proctor Haarwachstumanregung mit nitroxyd und anderen radikalen.
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
PL307127A1 (en) * 1992-07-10 1995-05-02 Boots Co Plc Therapeutic agents
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
IT1295694B1 (it) * 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
JP4136029B2 (ja) * 1997-05-12 2008-08-20 帝國製薬株式会社 硝酸イソソルビド含有貼付剤
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US6635273B1 (en) * 1999-10-29 2003-10-21 Trustees Of Boston University Methods of treating vascular diseases characterized by nitric oxide insufficiency

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104366475A (zh) * 2014-11-10 2015-02-25 罗会明 一种增强型保健品
CN104366475B (zh) * 2014-11-10 2016-01-20 罗会明 一种增强型保健品

Also Published As

Publication number Publication date
WO2002034303A1 (en) 2002-05-02
CA2678256A1 (en) 2002-05-02
EP1337283A4 (en) 2005-05-18
AU2001259399B2 (en) 2006-08-17
EP1337283A1 (en) 2003-08-27
AU2006236103A1 (en) 2006-12-07
AU2006236103B2 (en) 2009-04-02
JP2004521083A (ja) 2004-07-15
CA2421885A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
EP1244455A4 (en) METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY INSUFFICIENCY OF NITROGEN MONOXIDE
AU5939901A (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
GB2393202B (en) Methods of well treatment
EP1404343A4 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
EP1461027A4 (en) TREATMENT OF NEOPLASIA
HUP0200738A3 (en) Method of the treatment of incontinence
HRP20020729A2 (en) Treatment of psoriasis
GB0124124D0 (en) Methods of treatment
EP1389105A4 (en) METHOD OF TREATMENT
IL155769A0 (en) Method for the treatment of inflammation
GB2360453B (en) Treatment of skin conditions
GB0112216D0 (en) Method of treatment
AU9545701A (en) Use of carp inhibitors for the treatment of heart diseases
AU6137801A (en) Method and composition for the treatment of angiogenesis
GB0008921D0 (en) Method of treatment
IL154011A0 (en) Treatment of wounds
GB0118892D0 (en) Method of treatment
GB2399500B (en) Composition and method for treatment of wounds
IL149170A0 (en) Use of nitric oxide for the treatment of airway constriction
EP1402902A4 (en) VASCULAR REGENERATION THERAPY
EP1303281A4 (en) METHODS OF TREATMENT
IL161630A0 (en) Methods of treating endometreosis